ZOFRAN ODT Drug Patent Profile
✉ Email this page to a colleague
When do Zofran Odt patents expire, and what generic alternatives are available?
Zofran Odt is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in ZOFRAN ODT is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ondansetron profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zofran Odt
A generic version of ZOFRAN ODT was approved as ondansetron by CHARTWELL MOLECULES on December 26th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOFRAN ODT?
- What are the global sales for ZOFRAN ODT?
- What is Average Wholesale Price for ZOFRAN ODT?
Summary for ZOFRAN ODT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 136 |
| Clinical Trials: | 161 |
| Patent Applications: | 4,580 |
| Drug Prices: | Drug price information for ZOFRAN ODT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZOFRAN ODT |
| DailyMed Link: | ZOFRAN ODT at DailyMed |
Recent Clinical Trials for ZOFRAN ODT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tanta University | Phase 3 |
| Tanta University | Phase 2/Phase 3 |
| Emory University | Phase 2 |
US Patents and Regulatory Information for ZOFRAN ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-001 | Jan 27, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOFRAN ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-001 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-001 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-001 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Sandoz | ZOFRAN ODT | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 020781-002 | Jan 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOFRAN ODT
See the table below for patents covering ZOFRAN ODT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Greece | 3033937 | ⤷ Sign Up | |
| Mexico | 9703735 | COMPOSICIONES DE ONDANSETRON SECADAS POR CONGELACION. (FREEZE-DRIED ONDANSETRON COMPOSITIONS.) | ⤷ Sign Up |
| China | 1011237 | ⤷ Sign Up | |
| South Africa | 8500619 | ⤷ Sign Up | |
| Guatemala | 199000039 | COMPUESTOS HETEROCICLICOS. | ⤷ Sign Up |
| Greece | 850219 | ⤷ Sign Up | |
| Czech Republic | 285250 | Lyofilizovaný prostředek pro orální podávání (LYOPHILIZED PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
